HomeBUSINESS
BUSINESS

Sato, Eisai to Copromote Oral Onychomycosis Drug
(Oct.4.2017)

Sato Pharmaceutical and Eisai said on October 3 that they have agreed to copromote BFE1224 (fosravuconazole L-lysine ethanolate), a new triazole-class oral antifungal agent under review in Japan for the treatment of onychomycosis ...
(LOG IN FOR FULL STORY)

News Calendar